Clinical trial
Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease
NCT00195143 · Neurologix, Inc., Industry · Completed
Key facts
| NCT number | NCT00195143 |
|---|---|
| Title | Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease |
| Official title | Phase I Study of Subthalamic GAD Gene Transfer in Medically Refractory Parkinson's Disease Patients |
| Lead sponsor | Neurologix, Inc., Industry |
| Collaborators | Weill Medical College of Cornell University North Shore University Hospital |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Genetic |
| Interventions | Surgical infusion of AAV-GAD into the subthalamic nucleus |
| Enrollment | 12 |
| Start date | Aug 1, 2003 |
| Completion | Aug 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 27, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: